Tibet Weixinkang Medicine Co Ltd603676
▲ ポジティブ規制関連度
NMPA approved a new 20ml specification of its Potassium Aspartate Injection and deemed it passed consistency evaluation, a regulatory approval that supports future sales.
銘柄への影響 1
その他
Tibet Weixinkang Medicine Co Ltdテーマインパクト
カバレッジ外企業 1
洋浦京泰非上場▲ ポジティブ
規制関連度
The wholly-owned subsidiary received the NMPA supplementary application approval for the new specification and consistency evaluation of Potassium Aspartate Injection.